Merck TroFuse-015 Phase 3 Meets Survival Endpoint — CASRAI
Merck announced that its Phase 3 trial of sacituzumab tirumotecan (sac-TMT) met the primary endpoint of overall survival in patients with advanced gastroesophageal adenocarcinoma. The drug showed a statistically significant improvement in survival compared to physician's choice treatments, though secondary endpoints were not met. Full results will be presented at an upcoming medical meeting. Sac-TMT is not yet approved for any use.
How this was made
The 30-second read
Why it matters
The topline OS success is the key new decision-relevant item, but traders must wait for hazard ratio, median survival difference, p-values, and detailed safety to judge magnitude and durability. The PFS secondary endpoint not being met is a meaningful counter-signal.
Market read
A Phase 3 OS primary endpoint win can re-rate clinical-stage oncology risk, but incomplete statistical disclosure and a PFS miss reduce immediate clarity on label potential.
What to watch
Open-label design and the absence of prespecified statistical testing details for objective response may raise scrutiny when full results and safety granularity are released.
Background
TroFuse-015 is Merck’s global Phase 3 study of sacituzumab tirumotecan (sac-TMT, MK-2870) in third-line or later locally advanced unresectable or metastatic gastroesophageal adenocarcinoma versus physician’s choice chemotherapy.
Ticker impact
Merck announced TroFuse-015 Phase 3 sac-TMT met the overall survival primary endpoint in third-line or later gastroesophageal adenocarcinoma, with no new safety signals.
Likely upward bias as traders price improved clinical efficacy, tempered by uncertainty from missing effect-size details and the PFS miss.
The article is a first topline OS success in Phase 3, which is typically material for biotech risk, but it provides no hazard ratio, median survival, or p-values and reports PFS was not met.
Market effects
Supports sentiment for TROP2-directed antibody-drug conjugates and ADCs in solid tumors, while highlighting that OS can diverge from PFS.
No explicit regional market mechanism described beyond global trial execution.
Global Phase 3 readout can influence international oncology trial and regulatory expectations for ADC competitors.
Counterpoint
OS benefit without reported hazard ratio or median survival, plus a PFS miss, could indicate endpoint assay noise or post-progression effects that may not translate cleanly to label outcomes.
Key entities
- companyMerck
Sponsor of TroFuse-015 Phase 3; reported statistically significant overall survival improvement for sac-TMT.
- drugsacituzumab tirumotecan (sac-TMT, MK-2870)
TROP2-directed antibody-drug conjugate with belotecan-derived topoisomerase I inhibitor payload.
- clinical_trialTroFuse-015
Phase 3, randomized, open-label, multicentre global trial; primary endpoint is overall survival.
- companyKelun-Biotech
Developed the molecule; Merck holds exclusive license and collaboration rights outside Greater China.




